Literature DB >> 31403137

Optimising trial outcomes and patient retention for the MACRO trial for chronic rhinosinusitis.

N H Ta1, C Hopkins2, J Vennik3, C Philpott4.   

Abstract

BACKGROUND: This study aimed to evaluate current subjective and objective outcome assessments for the MACRO (defining best Management for Adults with Chronic RhinOsinusitis) Trial which compares antibiotics, placebo and sinus surgery. This was to identify any redundant assessments and to include patient perspectives to determine acceptability for confirmation in the trial.
METHODS: Adults CRS patients meeting the provisional eligibility criteria for the MACRO trial were recruited to this mixed-method study at 2 sites. Correlations between the objective outcome measures and SNOT-22 scores were evaluated. Selected participants took part in a semi-structured telephone interview to explore their experiences and views of undergoing outcome measures.
RESULTS: Seventy patients (37% male) were recruited, 36 had CRS without nasal polyps, 34 had CRS with nasal polyps. There was a weak inverse correlation between the SNOT-22 â€Blockage†ratings and Peak Nasal Inspiratory Flow readings, a moderate inverse correlation between the SNOT-22 â€Smell†ratings and Sniffin’ Sticks scores, but no significant correlation between the SNOT-22 and Saccharin test results. The participants’ experience of the trial visit was positive with an acceptable duration of trial visit. Most proposed outcome measures were valued by participants with the exception of the Saccharin test. DISCUSSION: The Sniffin’ Sticks test and PNIF correlate with their respective component SNOT-22 scores but are considered important by patients; PNIF is simple, cheap test to perform. The Saccharin test will be removed as participants did not value it and was not highly rated in parallel work on a core outcome set for CRS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31403137     DOI: 10.4193/Rhin19.142

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  2 in total

1.  Objective validity of patient-reported symptoms in aspirin-exacerbated respiratory disease patients.

Authors:  Pooja P Patel; Jing Cui; Katherine N Cahill; Tanya M Laidlaw
Journal:  Clin Exp Allergy       Date:  2021-12-01       Impact factor: 5.018

2.  Maximising recruitment to a randomised controlled trial for chronic rhinosinusitis using qualitative research methods: the MACRO conversation study.

Authors:  Clare McDermott; Jane Vennik; Carl Philpott; Steffi le Conte; Mike Thomas; Caroline Eyles; Paul Little; Helen Blackshaw; Anne Schilder; Claire Hopkins
Journal:  Trials       Date:  2021-01-13       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.